MedTrace Logo

Complex Imaging Assessment of Steatosis

NCT02669641 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-02-01

No results posted yet for this study

Summary

The main objective is the assessment of MRI (Magnetic Resonance Imaging) Spectroscopy in patients diagnosed with hepatic steatosis in treatment with combination Silimarin, Phyllanthus Niruri and Choline.

Conditions

Interventions

DIETARY_SUPPLEMENT

Combination Silimarin, Phyllanthus niruri and Choline

Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.

Sponsors & Collaborators

  • Fiterman Pharma SRL

    collaborator UNKNOWN

  • University of Medicine and Pharmacy Craiova

    lead OTHER

Principal Investigators

  • Ioana Andreea Gheonea, Lecturer · University of Medicine and Pharmacy Craiova

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-06-30
Completion
2016-12-31

Countries

  • Romania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02669641 on ClinicalTrials.gov